Jubilant Pharmova Q2 Results: Net profit falls as sterile injectables, radiopharma earnings decline

Jubilant Pharmova reported a 74.1% year-on-year decline in Q2 FY27 consolidated net profit to ₹31.2 crore, even as revenue from operations grew 20.5% to ₹2,370 crore. EBITDA fell 29.3% to ₹241 crore, with the margin narrowing to 10.2% from 17.4%.